Ibandronate vs Zoledronic Acid — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Bisphosphonate

Ibandronate

First FDA approval: 2012-03-19

Bisphosphonate

Zoledronic Acid

Brand: Reclast

First FDA approval: 2007-04-01

Lowest NADACAcquisition cost floor across all NDCs

$2.79Per unit

$0.465Per unit

Average NADACAcross all dosage forms and strengths

$16.82Up to $54.21

$0.465Up to $0.465

Generic manufacturersActive ANDA holders — FDA Orange Book

910 total ANDAs filed

1524 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$39.1MFull year

$612954Full year

Part D claims (CY24)Total fills, all strengths

1.3M489K beneficiaries

6K2K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$30Per claim, all NDCs

$101Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

55Minimal friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

2Limited friction

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes9 manufacturers

Yes15 manufacturers